Abstract
Objective: We report a case of neuroleptic malignant syndrome in a woman who assumed risperidone for schizoaffective disorders. Case Summary: A 45-year-old woman affected by schizoaffective disorders was admitted to Infectious Disease unit of Crotone Hospital because of a diagnosis of a fever of unknown origin. Clinical evaluation documented confusion and dysphoria, whereas chemical blood evaluation revealed acidosis and liver dysfunction. After few days she was transferred to the Operative Unit of Internal Medicine of San Giovanni in Fiore Hospital because of an increase in liver transaminases. Clinical evaluation showed the persistence of fever (38.8 degrees Celsius), with an increase in CPK, and liver enzymes. Pharmacological evaluation indicated a probable relationship between risperidone and NMS and led to a diagnosis of neuroleptic malignant syndrome associated with risperidone in a woman with schizophrenia. About seven days later, we recorded a complete resolution of her psychiatric symptoms. Discussion: We postulate a possible interaction between risperidone and neuroleptic malignant syndrome and we suggest to use risperidone with caution in both young and middle aged people.
Keywords: Risperidone, neuroleptic malignant syndrome, schizophrenic woman
Current Drug Safety
Title: A Case of Neuroleptic Malignant Syndrome Induced by Risperidone in a Schizophrenic Woman
Volume: 4 Issue: 2
Author(s): Luca Gallelli, Vincenzo Spagnuolo, Caterina Palleria, Giovambattista De Sarro and Maria Ferraro
Affiliation:
Keywords: Risperidone, neuroleptic malignant syndrome, schizophrenic woman
Abstract: Objective: We report a case of neuroleptic malignant syndrome in a woman who assumed risperidone for schizoaffective disorders. Case Summary: A 45-year-old woman affected by schizoaffective disorders was admitted to Infectious Disease unit of Crotone Hospital because of a diagnosis of a fever of unknown origin. Clinical evaluation documented confusion and dysphoria, whereas chemical blood evaluation revealed acidosis and liver dysfunction. After few days she was transferred to the Operative Unit of Internal Medicine of San Giovanni in Fiore Hospital because of an increase in liver transaminases. Clinical evaluation showed the persistence of fever (38.8 degrees Celsius), with an increase in CPK, and liver enzymes. Pharmacological evaluation indicated a probable relationship between risperidone and NMS and led to a diagnosis of neuroleptic malignant syndrome associated with risperidone in a woman with schizophrenia. About seven days later, we recorded a complete resolution of her psychiatric symptoms. Discussion: We postulate a possible interaction between risperidone and neuroleptic malignant syndrome and we suggest to use risperidone with caution in both young and middle aged people.
Export Options
About this article
Cite this article as:
Gallelli Luca, Spagnuolo Vincenzo, Palleria Caterina, De Sarro Giovambattista and Ferraro Maria, A Case of Neuroleptic Malignant Syndrome Induced by Risperidone in a Schizophrenic Woman, Current Drug Safety 2009; 4 (2) . https://dx.doi.org/10.2174/157488609788173062
DOI https://dx.doi.org/10.2174/157488609788173062 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Adipokines and Adipocyte Targets in the Future Management of Obesity and the Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry The Impact of Substance P on the Pathogenesis of Insulin Resistance Leading to Gestational Diabetes
Current Pharmaceutical Biotechnology Is There a Role for Cytokine Based Therapies in Fibromyalgia
Current Pharmaceutical Design Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis
Reviews on Recent Clinical Trials A New Protocol of Type 2 Diabetes Induction and Hydrocortisone Effects on Beta-Cells Signaling in Mice
Current Chemical Biology The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Plasma Steroid Level Measured Using Modern Separation Techniques as Biomarkers in Biological Diagnostics
Current Pharmaceutical Analysis Subject Index to Volume 9
Current Pharmaceutical Design Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Editorial: [Hot Topic: Non-Analgesic Effects of Opioids]
Current Pharmaceutical Design Emerging Concepts in Diabetes: Mitochondrial Dynamics and Glucose Homeostasis
Current Diabetes Reviews Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets
CNS & Neurological Disorders - Drug Targets Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Protective Substances Against Zinc-Induced Neuronal Death after Ischemia:Carnosine as a Target for Drug of Vascular Type of Dementia
Recent Patents on CNS Drug Discovery (Discontinued) Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Osteoporosis and its Association with Non-Gonadal Hormones Involved in Hypertension, Adiposity and Hyperglycaemia
Current Drug Targets Steroid 5α-Reductase Inhibitors
Mini-Reviews in Medicinal Chemistry Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets